These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17020970)

  • 1. Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients.
    Corrias MV; Haupt R; Carlini B; Parodi S; Rivabella L; Garaventa A; Pistoia V; Dallorso S
    Clin Cancer Res; 2006 Oct; 12(19):5680-5. PubMed ID: 17020970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
    Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
    Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry.
    Lode HN; Handgretinger R; Schuermann U; Seitz G; Klingebiel T; Niethammer D; Beck J
    Eur J Cancer; 1997 Oct; 33(12):2024-30. PubMed ID: 9516847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
    Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
    Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
    Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
    Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular assessment of minimal residual disease in PBSC harvests provides prognostic information in neuroblastoma.
    Chambon F; Tchirkov A; Pereira B; Rochette E; Deméocq F; Kanold J
    Pediatr Blood Cancer; 2013 Sep; 60(9):E109-12. PubMed ID: 23596146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma.
    Leung W; Chen AR; Klann RC; Moss TJ; Davis JM; Noga SJ; Cohen KJ; Friedman AD; Small D; Schwartz CL; Borowitz MJ; Wharam MD; Paidas CN; Long CA; Karandish S; McMannis JD; Kastan MB; Civin CI
    Bone Marrow Transplant; 1998 Nov; 22(10):971-9. PubMed ID: 9849694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation.
    Hardingham JE; Kotasek D; Sage RE; Dobrovic A; Gooley T; Dale BM
    Bone Marrow Transplant; 1993 Jan; 11(1):15-20. PubMed ID: 8381694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
    Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
    Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
    Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
    Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer.
    Chen LC; Brown AB; Cheung IY; Cheung NK; Kris MG; Krug LM
    Lung Cancer; 2010 Feb; 67(2):216-20. PubMed ID: 19457569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma.
    Handgretinger R; Lang P; Ihm K; Schumm M; Geiselhart A; Koscielniak E; Hero B; Klingebiel T; Niethammer D
    Bone Marrow Transplant; 2002 May; 29(9):731-6. PubMed ID: 12040469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
    Cheung IY; Cheung NK
    Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of autologous PB CD34+ cells provides a purging effect in children with neuroblastoma.
    Kanold J; Halle P; Tchirkov A; Berger M; Giarratana MC; Kobari L; Boiret N; Paillard C; Deméocq F; Douay L
    Bone Marrow Transplant; 2003 Sep; 32(5):485-8. PubMed ID: 12942094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
    Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cells are present in stem cell harvests of Ewings sarcoma patients and their persistence following transplantation is associated with relapse.
    Yaniv I; Cohen IJ; Stein J; Zilberstein J; Liberzon E; Atlas O; Grunshpan A; Sverdlov Y; Ash S; Zaizov R; Avigad S
    Pediatr Blood Cancer; 2004 May; 42(5):404-9. PubMed ID: 15049010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma.
    Ho J; Yang L; Banihashemi B; Martin L; Halpenny M; Atkins H; Sabloff M; McDiarmid SA; Huebsch LB; Bence-Bruckler I; Giulivi A; Allan DS
    Bone Marrow Transplant; 2009 Feb; 43(3):223-8. PubMed ID: 18820710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.